Intellia Therapeutics, Inc.

Good morning and welcome to the Intellia Therapeutics third quarter 2022 financial results conference call. My name is Andrew and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available at the company's website following the end of the call. As a reminder, all participants are currently in listen-only mode. If you require operator assistance, please press star then zero on your telephone keypad. I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intelia. Please proceed.

Thank you, Operator, and good morning, everyone. Welcome to Intelia Therapeutics' third quarter 2022 earnings call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors and Media section of Intellia's website and intelliatx.com. This call is being broadcast live, and a replay will be archived on the company's website. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intelia undertakes no duty to update this information unless required by law. Joining me from Intelia are Dr. John Leonard, Chief Executive Officer, Dr. David Levol, Chief Medical Officer, Dr. Laura Sepp-Lorenzino, Chief Scientific Officer, and Glenn Goddard, Chief Financial Officer. John will begin with an overview of recent business highlights, David will provide an update on our clinical program, Laura will then recap the company's R&D progress, and Glenn will review Intelia's financial results for the third quarter. John will then offer some concluding remarks before we open up the call for Q&A. With that, I'll now turn the call over to John.

Thank you, Ian, and thank you all for joining us this morning. At Intelia, we're building the industry's leading genome editing company by deploying the broadest and deepest toolbox. We're pioneering novel editing and delivery solutions to harness the immense power of CRISPR-based technologies for in vivo and ex vivo therapeutic applications, each with the potential to revolutionize medicine. During the third quarter and more recently, we've continued to execute against our strategic priorities as we advance our full spectrum pipeline and modular platforms. This includes achieving significant clinical milestones across our landmark first in human studies of NTLA-2001 and NTLA-2002. In September, we were delighted to share positive interim data from both clinical trials, which David will recap shortly. Both data sets demonstrate the potential for investigational therapies to be transformative, one-time treatments for people living with either ATTR amyloidosis or hereditary angioedema. By successfully editing a disease-causing gene, we showed for the first time that we can not only significantly reduce levels of the offending protein, but also in doing so, can elicit a clinically meaningful impact. Further, these data provide powerful evidence of the modularity of our platform and highlight the strong foundation on which we will move forward a pipeline of CRISPR-based therapies. We're looking forward to sharing additional interim data from these ongoing studies of NTLA-2001 and NTLA-2002 in the coming weeks. I'll now turn it over to David.